-
1
-
-
0037309635
-
Angiopoietins, growth factors, and vascular morphology in early arthritis
-
Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260268.
-
(2003)
J Rheumatol
, vol.30
, pp. 260268
-
-
Fearon, U.1
Griosios, K.2
Fraser, A.3
-
2
-
-
85018190193
-
Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features
-
Celis R, Planell N, Fernández-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012;27:R9.
-
(2012)
Arthritis Res Ther
, vol.27
, pp. R9
-
-
Celis, R.1
Planell, N.2
Fernández-Sueiro, J.L.3
-
3
-
-
85172635853
-
PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled SUMMIT 1 trial
-
McInnes IB, Kavanaugh A, Gottlieb AB, et al. PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, doubleblind, placebo-controlled SUMMIT 1 trial. Lancet 2013;382:7809.
-
(2013)
Lancet
, vol.382
, pp. 7809
-
-
McInnes, I.B.1
Kavanaugh, A.2
Gottlieb, A.B.3
-
4
-
-
84891898217
-
IL17A: A unique pathway in immune mediated diseases: Psoriasis, psoriatic arthritis, and rheumatoid arthritis
-
Kirkham BW, Kavanaugh A, Reich K. IL17A: a unique pathway in immune mediated diseases: psoriasis, psoriatic arthritis, and rheumatoid arthritis. Immunology 2014;141:13342.
-
(2014)
Immunology
, vol.141
, pp. 13342
-
-
Kirkham, B.W.1
Kavanaugh, A.2
Reich, K.3
-
5
-
-
84886951567
-
The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies
-
Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: Perspectives and validated strategies. Autoimmun Rev 2013;13:001511.
-
(2013)
Autoimmun Rev
, vol.13
, pp. 001511
-
-
Novelli, L.1
Chimenti, M.S.2
Chiricozzi, A.3
-
6
-
-
0030765924
-
Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?
-
O'Shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 1997;7:11-13.
-
(1997)
Immunity
, vol.7
, pp. 11-13
-
-
O'Shea, J.J.1
-
7
-
-
79955027327
-
Modulation of innate and adaptive immune responses by tofacitinib (CP690,550)
-
Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP690,550). J Immunol 2011;7:4234-43.
-
(2011)
J Immunol
, vol.7
, pp. 4234-4243
-
-
Ghoreschi, K.1
Jesson, M.I.2
Li, X.3
-
8
-
-
84857239335
-
The JAK inhibitor CP690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: Autocrine role of type I interferon
-
Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012;71:4407.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 4407
-
-
Rosengren, S.1
Corr, M.2
Firestein, G.S.3
-
9
-
-
84873188114
-
STAT1 expression and activation is increased in lesional psoriatic skin
-
Hald A, Andrés RM, Salskov Iversen ML, et al. STAT1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol 2013;168: 302-10.
-
(2013)
Br J Dermatol
, vol.168
, pp. 302-310
-
-
Hald, A.1
Andrés, R.M.2
Salskov Iversen, M.L.3
-
10
-
-
84856459600
-
Podoplanin expression in wound and hyperproliferative psoriatic epidermis: Regulation by TGFβ and STAT3 activating cytokines, IFNγ, IL6, and IL22
-
Honma M, Minami Hori M, Takahashi H, et al. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGFβ and STAT3 activating cytokines, IFNγ, IL6, and IL22. J Dermatol Sci 2012;65: 134-40.
-
(2012)
J Dermatol Sci
, vol.65
, pp. 134-140
-
-
Honma, M.1
Minami Hori, M.2
Takahashi, H.3
-
11
-
-
85018161888
-
The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis
-
Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;71: 440-7.
-
(2015)
Ann Rheum Dis
, vol.71
, pp. 440-447
-
-
Boyle, D.L.1
Soma, K.2
Hodge, J.3
-
12
-
-
84893729220
-
JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T-helper17 expansion in psoriatic arthritis
-
Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T-helper17 expansion in psoriatic arthritis. Immunol Res 2014;58:61-9.
-
(2014)
Immunol Res
, vol.58
, pp. 61-69
-
-
Fiocco, U.1
Accordi, B.2
Martini, V.3
-
13
-
-
84868092910
-
Modulation of STAT3 in rheumatoid synovial T-cells suppresses Th17 differentiation and increases the proportion of Treg cells
-
Ju JH, Heo YJ, Cho ML, et al. Modulation of STAT3 in rheumatoid synovial T-cells suppresses Th17 differentiation and increases the proportion of Treg cells. Arthritis Rheum 2012;64:3543-52.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 3543-3552
-
-
Ju, J.H.1
Heo, Y.J.2
Cho, M.L.3
-
14
-
-
84934985384
-
Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis
-
Gao W, McCormick J, Connolly M, et al. Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis. Ann Rheum Dis 2015;74:1275-83.
-
(2015)
Ann Rheum Dis
, vol.74
, pp. 1275-1283
-
-
Gao, W.1
McCormick, J.2
Connolly, M.3
-
15
-
-
79960889850
-
Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells
-
Akca H, Demiray A, Tokgun O, et al. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer 2011;73:302-9.
-
(2011)
Lung Cancer
, vol.73
, pp. 302-309
-
-
Akca, H.1
Demiray, A.2
Tokgun, O.3
-
16
-
-
84897019848
-
Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo
-
Yokota K, Sato K, Miyazaki T, et al. Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheum 2014;66:121-9.
-
(2014)
Arthritis Rheum
, vol.66
, pp. 121-129
-
-
Yokota, K.1
Sato, K.2
Miyazaki, T.3
-
17
-
-
84867077631
-
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production
-
LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012;64:353-14.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 353-414
-
-
LaBranche, T.P.1
Jesson, M.I.2
Radi, Z.A.3
-
18
-
-
84883588577
-
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte derived dendritic cells
-
Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte derived dendritic cells. Ann Rheum Dis 2014;73:219-28.
-
(2014)
Ann Rheum Dis
, vol.73
, pp. 219-228
-
-
Kubo, S.1
Yamaoka, K.2
Kondo, M.3
-
19
-
-
84861827087
-
The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin17 production by human CD4+ T cells
-
Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin17 production by human CD4+ T cells. Arthritis Rheum 2012;64:1790-8.
-
(2012)
Arthritis Rheum
, vol.64
, pp. 1790-1798
-
-
Maeshima, K.1
Yamaoka, K.2
Kubo, S.3
|